Fingolimod is approved for the treatment of relapsing-remitting multiple sclerosis (MS), and evidence suggests that it has neuroprotective effects. The recent INFORMS phase III trial in primary progressive MS demonstrated no beneficial effects of fingolimod on disability progression or whole-brain atrophy, but provides important information for future therapeutic development.
Bibliographical noteFunding Information:
A.L.S. is supported by a National Multiple Sclerosis Society Sylvia Lawry Physician Fellowship Award (FP 17117-A-2).
© 2016 Macmillan Publishers Limited. All rights reserved.